Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.55 |
| ▸ | EGFR | P00533 | 8/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13404547 | 0.90 | KDR (0.57) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13404545 | 0.87 | EGFR (0.54) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13404542 | 0.86 | EGFR (0.56) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13404548 | 0.85 | KDR (0.56) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6046888 | 0.80 | KDR (0.58) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13404539 | 0.79 | EGFR (0.53) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13404535 | 0.77 | EGFR (0.53) | KDREGFR | |
| SCHEMBL14765531 | 0.76 | SRC (0.52) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13404537 | 0.75 | EGFR (0.47) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13404536 | 0.75 | EGFR (0.54) | KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | disclosed |
| US-7648975-B2 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105668-A1 | Quinazoline derivatives | NR1H2, NR1H3, NR3C2 | KDR 2393/4885HDAC3 224/4885HDAC4 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.